Argenx jumps on Phase 3 data for blockbuster Vyvgart
The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.